BDTX
Price
$2.70
Change
+$0.01 (+0.37%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
152.69M
104 days until earnings call
Intraday BUY SELL Signals
CGEN
Price
$1.59
Change
+$0.03 (+1.91%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
141.24M
77 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BDTX vs CGEN

Header iconBDTX vs CGEN Comparison
Open Charts BDTX vs CGENBanner chart's image
Black Diamond Therapeutics
Price$2.70
Change+$0.01 (+0.37%)
Volume$25.46K
Capitalization152.69M
Compugen
Price$1.59
Change+$0.03 (+1.91%)
Volume$2.22K
Capitalization141.24M
BDTX vs CGEN Comparison Chart in %
BDTX
Daily Signal:
Gain/Loss:
CGEN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BDTX vs. CGEN commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDTX is a Hold and CGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (BDTX: $2.69 vs. CGEN: $1.57)
Brand notoriety: BDTX and CGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BDTX: 826% vs. CGEN: 28%
Market capitalization -- BDTX: $152.69M vs. CGEN: $141.24M
BDTX [@Biotechnology] is valued at $152.69M. CGEN’s [@Biotechnology] market capitalization is $141.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BDTX’s FA Score shows that 0 FA rating(s) are green whileCGEN’s FA Score has 1 green FA rating(s).

  • BDTX’s FA Score: 0 green, 5 red.
  • CGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, BDTX is a better buy in the long-term than CGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BDTX’s TA Score shows that 4 TA indicator(s) are bullish while CGEN’s TA Score has 4 bullish TA indicator(s).

  • BDTX’s TA Score: 4 bullish, 5 bearish.
  • CGEN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both BDTX and CGEN are a bad buy in the short-term.

Price Growth

BDTX (@Biotechnology) experienced а -28.84% price change this week, while CGEN (@Biotechnology) price change was -1.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.75%. For the same industry, the average monthly price growth was +5.41%, and the average quarterly price growth was +55.63%.

Reported Earning Dates

BDTX is expected to report earnings on Mar 18, 2026.

CGEN is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BDTX($153M) has a higher market cap than CGEN($141M). CGEN has higher P/E ratio than BDTX: CGEN (64.00) vs BDTX (7.27). BDTX YTD gains are higher at: 25.701 vs. CGEN (2.614). BDTX has higher annual earnings (EBITDA): 5.05M vs. CGEN (-19.81M). BDTX has more cash in the bank: 143M vs. CGEN (93.9M). CGEN has less debt than BDTX: CGEN (2.97M) vs BDTX (20.8M). BDTX has higher revenues than CGEN: BDTX (70M) vs CGEN (22.1M).
BDTXCGENBDTX / CGEN
Capitalization153M141M109%
EBITDA5.05M-19.81M-25%
Gain YTD25.7012.614983%
P/E Ratio7.2764.0011%
Revenue70M22.1M317%
Total Cash143M93.9M152%
Total Debt20.8M2.97M700%
FUNDAMENTALS RATINGS
BDTX vs CGEN: Fundamental Ratings
BDTX
CGEN
OUTLOOK RATING
1..100
597
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6296
PRICE GROWTH RATING
1..100
4062
P/E GROWTH RATING
1..100
9919
SEASONALITY SCORE
1..100
n/a7

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BDTX's Valuation (49) in the null industry is somewhat better than the same rating for CGEN (85) in the Biotechnology industry. This means that BDTX’s stock grew somewhat faster than CGEN’s over the last 12 months.

BDTX's Profit vs Risk Rating (100) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that BDTX’s stock grew similarly to CGEN’s over the last 12 months.

BDTX's SMR Rating (62) in the null industry is somewhat better than the same rating for CGEN (96) in the Biotechnology industry. This means that BDTX’s stock grew somewhat faster than CGEN’s over the last 12 months.

BDTX's Price Growth Rating (40) in the null industry is in the same range as CGEN (62) in the Biotechnology industry. This means that BDTX’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for BDTX (99) in the null industry. This means that CGEN’s stock grew significantly faster than BDTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BDTXCGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
BDTX
Daily Signal:
Gain/Loss:
CGEN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SGSOF115.273.38
+3.02%
SGS SA
QRNNF2.45N/A
N/A
Aurizon Holdings Ltd.
JSEJF7.89-0.03
-0.34%
Jse Ltd.
FNICF0.02N/A
-0.98%
Fathom Nickel Inc.
SRCRF0.25N/A
-1.66%
Scorpio Gold Corp.

BDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BDTX has been loosely correlated with RLAY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BDTX jumps, then RLAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BDTX
1D Price
Change %
BDTX100%
-22.03%
RLAY - BDTX
50%
Loosely correlated
+4.54%
RXRX - BDTX
43%
Loosely correlated
+7.87%
BEAM - BDTX
43%
Loosely correlated
+14.42%
CRBU - BDTX
43%
Loosely correlated
+5.68%
DNLI - BDTX
43%
Loosely correlated
+6.50%
More

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
+3.97%
NURPF - CGEN
46%
Loosely correlated
+13.08%
ASPHF - CGEN
41%
Loosely correlated
N/A
BDTX - CGEN
40%
Loosely correlated
-22.03%
ORMP - CGEN
40%
Loosely correlated
-1.09%
ABCL - CGEN
38%
Loosely correlated
+0.87%
More